Reply to 'Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers'
ESMO Open
.
2017 Oct 23;2(4):e000281.
doi: 10.1136/esmoopen-2017-000281.
eCollection 2017.
Authors
Georgios Bakalos
1
2
,
Thomas Schreitmüller
3
Affiliations
1
Global Product Development Medical Affairs, Hoffmann-La Roche Ltd, Basel, Switzerland.
2
Department of Biomathematics, University of Thessaly School of Medicine, Larisa, Greece.
3
Roche Pharma Technical Operations, Hoffmann-La Roche Ltd, Basel, Switzerland.
PMID:
29104764
PMCID:
PMC5663272
DOI:
10.1136/esmoopen-2017-000281
No abstract available
Keywords:
biologic; biosimilars; monoclonal antibodies; reference product; switching.